Status:
COMPLETED
A Study of LY3471851 in Participants With Eczema
Lead Sponsor:
Nektar Therapeutics
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Dermatitis, Atopic
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to learn more about the safety and side effects of LY3471851 when given by injection just under the skin to participants with eczema. The study will last up to 48 wee...
Eligibility Criteria
Inclusion
- Have a confirmed diagnosis of atopic dermatitis (AD) for least 12 months
- Have active AD according to study specific criteria
- Be willing and able to undergo skin biopsies
Exclusion
- Have received certain topical medications for AD within 14 days prior to baseline
- Have received certain systemic medications for AD within 4 weeks prior to baseline
- Have received LY3471851 previously
Key Trial Info
Start Date :
December 4 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 24 2022
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04081350
Start Date
December 4 2019
End Date
June 24 2022
Last Update
February 20 2024
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Arkansas Research Trials, LLC
North Little Rock, Arkansas, United States, 72117
2
California Dermatology & Clinical Research Institute
Encinitas, California, United States, 92024
3
Center For Dermatology Clinical Research, Inc.
Fremont, California, United States, 94538
4
Therapeutics Clinical Research
San Diego, California, United States, 92123